Oric Pharmaceuticals
SOUTH SAN FRANCISCO, CA · Biotechnology · 133 employees
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regim
Funding history
- Funding Round — $264.0M — Feb 2026
- Funding Round — $125.0M — Jun 2025
- Funding Round — $125.0M — Jan 2024
- Funding Round — $125.0M — Jan 2024
- Funding Round — $85.0M — Jul 2023
Recent signals
- Mar 31, 2026: SEC 8-K (8.01): On March 31, 2026, ORIC Pharmaceuticals, Inc. presented a program update regarding rinzimetostat (ORIC-944), specifically discussing recent dose optimization data from the ongoing Phase 1b trial. This update provides significant insights into the trial's progress and potential implications for the treatment’s efficacy. The detailed findings were shared in a presentation attached as Exhibit 99.1, illustrating the updated data and methodologies applied. The event is crucial as it could impact future developments in the company's product offerings and clinical strategies.
- Feb 23, 2026: Raised $264.0M
- Jun 06, 2025: Raised $125.0M
- Jul 16, 2024: ORIC Pharmaceuticals Announces Clinical Collaborations with Bayer and Johnson & Johnson for Prostate Cancer Treatment
- Jan 30, 2024: Raised $125.0M
- Jan 24, 2024: Raised $125.0M
- Jul 05, 2023: Raised $85.0M
See plans & pricing → Track Oric Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.